...Migragen sold their joint rights to a patent application covering Rho kinase inhibitors to SCH. Migragen...
...placebo after eight weeks in a Phase II trial in 84 patients with stable angina. Migragen...

...Morphochem (Munich, Germany) and Migragen (Tuebingen, Germany) sold their joint rights to a patent application covering...
...their joint rights to a patent application covering Rho kinase inhibitors to Schering (FSE:SCH; SHR). Migragen...
...which filed for insolvency last year, was developing Rho kinase inhibitors with Morphochem . The Migragen...

...to a nerve regeneration technology to develop and market. The parties jointly developed the technology. Migragen...

...nanomolar concentrations, indicating that RGM can specifically guide axon formation. DeveloGen AG , Gottingen, Germany Migragen...

...CNS and cancer play Migragen (Tuebingen, Germany) hired Lucio van Rooijen as president and CEO. van...

...Migragen’s targets and cell-based and animal model assays. The partners will jointly own resulting compounds. Migragen...

...technology for identifying small molecules with Migragen 's targets and cell-based and animal model assays. Migragen...